New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Dr. John Cush RheumNow
2 months ago
Diet as a DMARD? The Evidence Is Still Hard to Swallow
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease https://t.co/BLrr3CNZMg
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
Aurelie Najm AurelieRheumo
2 months ago
Can AI spot RA inflammation from a thermal hand scan?
Cohort 100 RA pts
AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87
Main features wrist temperature & heat-pattern
With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI
Aurelie Najm AurelieRheumo
2 months ago
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and reserve biologics for patients who fail those. According to a new phase 3 trial presented at EULAR 2026, there may be a different way to approach this.
Aurelie Najm AurelieRheumo
2 months ago
A biomarker for CV disease in RA?
Anti-CXCR3 antibodies asso w/ atherosclerosis
Confirmed in a validation cohort
Adding Ab profile to the mSCORE increases
AUC from 0.6 to 0.9
Sens from 30 to 69%
How does it compare with other ways of detecting atherosclerosis?
#POS0899 https://t.co/O7bsLrVyzo
Janet Pope Janetbirdope
2 months ago
How to treat #RA-#ILD
Similar to #IPF
Occurs older men esp
Smoking risk
Vaccines
Etc
Philippe Dieude
#HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF
Nelly ZIADE 🍀 Nellziade
2 months ago
Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/uTxEJqbDBm
Janet Pope Janetbirdope
2 months ago
Controversial
#Rheumatoid #arthritis disease activity
May not affect #ILD
BUT affects #mortality
level evidence +/-
PHillippe Dieude said
#Rx from RCTs
#IS
Ex #rituximab
#antifibrotics
#nintedanib
#nerandomilast
HOw to Treat RA-ILD June 5
#EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Nelly ZIADE 🍀 Nellziade
2 months ago
Which b/tsDMARDs are NOT effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/hqfLAYeri3
sheila RHEUMarampa
2 months ago
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
Dr. John Cush RheumNow
2 months ago
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Nelly ZIADE 🍀 Nellziade
2 months ago
Which b/tsDMARDs are effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/8mj24lAOTk
sheila RHEUMarampa
2 months ago
What b/ts DMARDs are effective and not effective in axSpA?
Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA.
@RheumNow #EULAR2026 https://t.co/5udGPB1Hrr
